Business Standard

Tuesday, December 24, 2024 | 11:37 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Jubilant Life: Getting back on track

Improvement in margins and lower debt should help increase net profits

Jubilant Life: Getting back on track
Premium

Ujjval Jauhari
The Jubilant Life Sciences stock has been declining in the first half of FY18 on the back of a muted business performance.
A delay in contract manufacturing orders, pricing pressure in generics and integration of an acquisition impacted the company’s margins. The stock has, however, witnessed a recovery since October on expectations of an improvement in growth outlook.

The confidence on the company’s future prospects stems from improving outlook of its pharma segment (radio pharma products) and growing contract manufacturing (CMO) order book. The radio pharma (formulations with radioactive substances used in diagnosis or therapy) prospects has significantly improved after the completion

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in